GLP-1 is everywhere, policies are fragmented, and sports is getting smarter.

Today's reads show GLP-1 drugs shaping everything from joint pain to gym programming, while policy battles signal a fragmented future for health and global preparedness.

In today's read: 1. GLP-1 expands beyond weight loss, driving new markets. · 2. Policy fragmentation hinders public health and biotech innovation. · 3. AI is in the clinic, but human trust is still the gatekeeper. · 4. Performance science focuses on sustainable longevity. · 5. Metabolic health is increasingly linked to environmental and dietary diversity.

1. GLP-1 expands beyond weight loss, driving new markets.

GLP-1 receptor agonists like semaglutide and tirzepatide engage metabolic pathways beyond simple glucose regulation. This systemic action influences inflammation, cardiovascular health, and even joint tissue repair. Unit economics are compelling because patients stay on the drugs for long periods.

Watch for these drugs to become default treatments for conditions like osteoarthritis, expanding their market footprint. Pharma will push early access aggressively. Gyms are already figuring out how to serve this new GLP-1 patient, creating a new service category.

Evidence from today:

• Study Ranks GLP-1s for Cardiovascular Health — Mindbodygreen — A new study published in the New England Journal of Medicine found that specific GLP-1 medications, notably semaglutide (Ozempic/Wegovy) and tirzepatide (Zepbound/Mounjaro), showed better cardiovascular outcomes compared to dulaglutide (Trulicity). This suggests that not all GLP-1s are created equal for heart health, pushing patients and doctors to consider specific drug profiles beyond just weight loss.
• 4Moving Biotech finishes Phase 2a trial for GLP-1 knee pain jab — Longevity Technology — 4Moving Biotech just wrapped up enrollment for its Phase 2a trial of 4P004, an intra-articular GLP-1 receptor agonist for knee osteoarthritis. This randomized, double-blind, placebo-controlled study included 129 patients across Europe and the US. The drug aims to target inflammatory mechanisms behind pain and disease progression.
• Lilly expands GLP-1 access after Gilead HIV drug win — STAT News — Eli Lilly is expanding access to its GLP-1 peptide retatrutide through clinical trials, after Gilead won a lawsuit concerning the development pace of its HIV medicine. The move could get the new triple-agonist into more hands sooner, shaping the next wave of metabolic health.
• Lilly expands early access for unapproved obesity drug Retatrutide — STAT News — Eli Lilly just opened up its early access program for retatrutide, an experimental GLP-1 drug for obesity, to more patients. This means more people can try the drug before it's officially approved, potentially getting a jump on weight management. It's a calculated move to gather more real-world data and build anticipation ahead of regulatory decisions.
• Gyms Now Offer GLP-1 Support, Muscle Preservation Workouts — Athletech News — A new report from Inspire360 finds that gyms are getting in on the GLP-1 trend, rolling out programs focused on muscle preservation for members on these meds. They're partnering with telehealth platforms and expanding wellness services to keep up with the demand.

2. Policy fragmentation hinders public health and biotech innovation.

When policy is reactive and inconsistent, it creates uncertainty. This slows down the adoption of new health measures, creates access inequities, and makes it harder for biotech to navigate regulatory hurdles. Political noise erodes trust in central institutions.

Expect continued localized approaches to global problems like vaccines and tick control. Biotech innovations, especially in complex areas like gene editing, will face higher barriers and slower adoption until regulatory pathways become clearer and less burdensome. This favors well-capitalized players.

Evidence from today:

• Startup scraps plans for custom CRISPR gene therapies for babies — STAT News — Aurora Therapeutics, a startup co-founded by Nobel laureate Jennifer Doudna, suddenly shut down its program to create custom CRISPR therapies for infants with ultra-rare genetic diseases. They were trying to scale individualized treatments for conditions like Baby KJ's, but found FDA standards for gene-editing difficult for a small company to meet. Beam Therapeutics, another gene-editing company, will now take over some of the work.
• Pediatricians Create New Vaccine Guides After CDC Trust Dip — KFF Health News — Some pediatricians and public health departments are creating their own vaccine guidelines and resources. This comes after the Trump administration's shifts in CDC vaccine advice left many doctors questioning the agency's reliability. They're trying to give families trusted information when the usual source feels compromised.
• US still unprepared for next global health crisis — The Atlantic - Health — The Atlantic reports on the US government's persistent failure to learn lessons from past pandemics like Ebola, despite improvements in global disease control. This lack of sustained investment and coordination leaves the country vulnerable to future health crises, impacting everything from supply chains to healthcare access when the next big one hits.
• US needs a bigger plan to control its tick problem — The Atlantic - Health — The US public health system is struggling to contain tick-borne illnesses like Lyme disease, a problem that's getting worse as ticks spread to new areas. The Atlantic argues we need a coordinated national strategy, not just local efforts, to protect people from these nervous system-affecting infections.
• Trans federal employees sue over health coverage cuts — STAT News — A group of trans federal employees is suing the government after their health coverage for gender-affirming care was revoked. The lawsuit, filed in federal court, challenges the policy change, arguing it discriminates against trans individuals and denies them essential medical services. This move could set a precedent for insurance coverage of gender-affirming care nationally.

3. AI is in the clinic, but human trust is still the gatekeeper.

AI offers tools for faster diagnosis and treatment, but humans respond to its outputs differently. Clinicians prioritize seeing the reasoning, while laypeople are swayed by the 'why.' This disconnect impacts adoption and effectiveness.

AI diagnostic tools will struggle for broad clinical acceptance if they don't show their work. Companies need to design AI explanations for the specific user, not just for accuracy. Trust and transparency are the bottlenecks for scaling AI in healthcare.

Evidence from today:

• AI Skin Diagnosis Still Needs a Human Touch — Nature Medicine RSS — New research in Nature Medicine found that while AI can spot skin conditions accurately, showing its reasoning actually made clinicians trust it less. Lay people, on the other hand, trusted the AI more when they saw the 'why' behind its diagnosis. The study involved hundreds of participants and showed a clear divergence in how different groups perceive AI transparency.
• Most people can't spot AI-written personal messages, study finds — Videnskab.dk (Health) — A new study reveals that humans are surprisingly bad at telling whether a personal message was generated by AI or written by another human. While we say we don't like AI-generated content in personal exchanges, most of us can't actually identify it. This has implications for how we perceive authenticity and connection in digital communication.
• UK regulator eyes AI scribes as medical devices, not just software — STAT Health Tech — The UK's MHRA is exploring whether AI scribes, currently classified as software, should be regulated as medical devices. This move could bring stricter oversight for tools that capture and summarize clinical conversations. It's a big deal for health tech companies selling these tools across the pond.

4. Performance science focuses on sustainable longevity.

Elite athletes are optimizing not just for peak performance, but for long-term physical health. This involves integrating recovery, precise training load management, and biomechanical analysis to prevent injury and extend careers. The mechanism is adaptive load management.

The focus on low-intensity training and recovery in elite sports will trickle down to general fitness. Expect more tools that monitor physical stress and recovery metrics, helping everyday exercisers train smarter, not just harder. This creates demand for advanced wearables and recovery services.

Evidence from today:

• Olympic Race Walker Hits 82% Low-Intensity Training for Paris — Front. Sports & Active Living — New research tracked a female Olympic champion's training for the Paris 2024 Games, revealing she logged 3,719 km of race walking with a whopping 81.9% at low intensity. This longitudinal case study published in Frontiers in Sports & Active Living followed her from December 2023 to July 2024, confirming a pyramidal training distribution emphasizing endurance over speed work for peak performance.
• Editorial explores biomechanics, tech for sustainable athletic health — Front. Sports & Active Living — This new editorial in Frontiers in Sports & Active Living dives into how biomechanics and technology are shaping athletic performance. It looks at how monitoring tools and data help athletes stay healthy long-term. Basically, it's about using smart tech to keep bodies from breaking down.
• New research explores physical activity for older adults with spinal cord injury — Front. Sports & Active Living — A new study in Frontiers in Sports & Active Living interviewed 74 older adults (56–88 years) with long-term spinal cord injuries (SCI) in Sweden. It found that while physical activity (PA) offers significant benefits, restricted access makes it hard for this group to participate. The research outlines key barriers and facilitators for PA engagement in this population.
• High cardiorespiratory fitness predicts lower disease risk — Sports Medicine (Springer) — A meta-analysis of 31,171 observations confirmed high cardiorespiratory fitness (CRF) is a strong predictor of lower cardiovascular disease risk and mitochondrial disorders. The research, published in Sports Medicine, highlights CRF's role as a reliable health screening tool.
• High-impact sports may reduce hip replacement surgeries — Deutsches Ärzteblatt — New research from the University of Essex and the University of Southern Denmark suggests high-impact activities might actually protect hip joints and reduce the need for replacement surgery. The study followed over 500 former elite athletes, finding that these athletes had fewer hip replacements later in life than expected.

5. Metabolic health is increasingly linked to environmental and dietary diversity.

Our internal biology is shaped by external factors. Microplastics create systemic inflammation. A diverse diet feeds a diverse gut microbiome. Climate impacts body regulation. These external forces directly influence metabolic function, hormonal balance, and the nervous system's capacity.

Environmental health will become a more explicit part of longevity and metabolic discussions. This translates into consumer demand for 'clean' products and food with provenance. Regulators will eventually have to address environmental contaminants as a public health crisis.

Evidence from today:

• Microplastics linked to heart attack risk in new study — Deutsches Ärzteblatt — A small Italian study found higher concentrations of micro- and nanoplastics in the blood of severe heart attack patients compared to those with chronic heart disease or healthy vessels. Published in the European Heart Journal, this research adds to concerns about environmental pollutants impacting cardiovascular health.
• Flea treatments on pets threaten human health, wildlife — New Scientist — Decades of using preventive flea and tick treatments on pets have been based on the assumption they're safe for humans and wildlife. New research is showing this isn't the case, with growing evidence of negative health effects. This impacts everything from our waterways to our own nervous systems.
• Your gut needs a diverse diet, not just more vegetables — Mindbodygreen — Forget endlessly upping your veggie intake. New advice suggests it's the variety of your plant foods, not just the sheer quantity, that really feeds your gut microbiome. This means a mix of different plants matters more for gut health than just eating more of the same few.
• History of PCOS or endometriosis links to higher hot flash risk — Mindbodygreen — New research found women with a history of PCOS or endometriosis had a 52% higher risk of experiencing frequent hot flashes during menopause. The study, published in Menopause, looked at self-reported data from over 1,700 women. It suggests hormonal histories play a bigger role in perimenopausal symptoms than we thought.

Also moved today

• Outside Online calls for more women over 50 in outdoor media — Outside Online — Outdoor media's exclusion of women over 50 signals a market missing out on a growing, active demographic, ignoring real consumer signals.
• Postpartum mom finds sleep with magnesium, GABA, lemon balm — Mindbodygreen — Targeted sleep supplements combining ingredients like magnesium, GABA, and lemon balm show real-world effectiveness for postpartum insomnia, pointing to a stressed nervous system.
• Low Vitamin D Linked to More Back Pain and Spine Surgery — Mindbodygreen — Low vitamin D levels in most spine surgery patients suggest a simple nutritional intervention could reduce opioid use and shorten hospital stays, highlighting basic physiological gaps.
• Screen Time Tied to Brain Changes 20 Years Later — Mindbodygreen — Midlife screen time links to changes in brain white and gray matter two decades later, but passive viewing like TV is worse than active use, differentiating the neural impact of media consumption.
• UltraPod converts old iPhones into music-first dumbphones — Product Hunt — Health & Fitness — The UltraPod app turns old iPhones into music-only 'dumbphones,' responding to consumer demand for digital detox and focused attention without buying new hardware.
• Fake Paramedic Appeals Manslaughter Conviction in Germany — Deutsches Ärzteblatt — A fake paramedic appealing a manslaughter conviction in Germany reveals critical gaps in oversight of medical professionals and the real human cost of credentialing failures.
• Germany mulls mandatory civilian service amid military draft talks — Deutsches Ärzteblatt — Germany's consideration of mandatory civilian service to support health and elder care suggests a looming labor crisis in social services and a re-evaluation of national civic duty.
• THC reduces nightmares in PTSD patients in new Charité study — Deutsches Ärzteblatt — THC's ability to reduce nightmares in PTSD patients highlights a targeted treatment for nervous system dysregulation, moving past generalized sleep aids.
• Altimmune starts Phase 3 trial for fatty liver drug pemvidutide — Longevity Technology — Altimmune's Phase 3 trial for pemvidutide, targeting both glucagon and GLP-1 receptors, shows drug developers are looking beyond single-pathway interventions for metabolic disease.
• Garmin launches CIRQA smart band, ditching screen and subscriptions — Product Hunt — Health & Fitness — Garmin's new screenless CIRQA smart band, devoid of subscriptions, targets users seeking unobtrusive, long-term health tracking without digital distraction.

New this week in wellness goods

• Topo Athletic launches new carbon-plated racing shoe for speed — global — Topo Athletic just dropped the Specter Elite, its first carbon-plated racing shoe. This move aims to boost speed for runners with a specific foot geometry, adding more spring to your step on race day.
• UltraPod converts old iPhones into music-first dumbphones — global — UltraPod, a new app, lets you repurpose an old iPhone into a music-only device, stripping out most smart features. It aims to reduce screen time and digital distractions, offering a dedicated tool for focused listening without notifications. This gives old tech new life and a way to consciously manage your attention.
• Haut.AI launches software for remote skin research — B2B — Haut.AI released new Clinical Studies Software, a platform for beauty, skincare, and dermatology companies to run remote and hybrid clinical trials. It standardizes image capture and AI measurement for 48 skin biomarkers like wrinkles, pigmentation, and acne. This means companies can test products faster and at a larger scale.
• Ex-SkinCeuticals Execs Launch Relab for Psoriasis Before Flare-Ups — dermatological — Former executives from SkinCeuticals and Murad launched Relab, a new skincare brand focused on preventing psoriasis flare-ups. The brand uses biotechnology-backed solutions to tackle chronic conditions like psoriasis, eczema, rosacea, and dermatitis. This signals a shift in the skincare industry towards addressing stigmatized skin conditions with targeted, preventative care.
• AI Device Scans Throat for Routine Physicals, No Swab Needed — Japan — A Japanese startup, Nodoca, developed an AI-powered device that scans the throat for physical exams, ditching the dreaded nasal swab. This less intrusive system could make routine health screenings a lot less uncomfortable for everyone. Think quick, easy, and maybe even a little futuristic.
• Garmin launches CIRQA smart band, ditching screen and subscriptions — global — Garmin just dropped the CIRQA smart band, a screenless health and fitness tracker that skips the monthly subscription fees. It's meant to be worn 24/7 to gather biometric data without demanding constant attention. This puts Garmin squarely in the minimal-tech, long-term health tracking lane.
• New oral care brands target microbiome and novel ingredients — Three new oral care brands — Köppen, Evenmouth, and Bastét — are launching products designed to disrupt the dental hygiene market. They're using multi-step systems, microbiome-focused protocols, and new ingredients to move beyond traditional brushing.
• Hims & Hers sees 88% adherence for its first gummy prescription — Hims & Hers reports an 88% daily adherence rate for its new gummy prescription medication. This makes it another win for the gummy format, which wellness and beauty brands are increasingly leveraging for better consumer compliance. For Hims & Hers, it's also about nailing a business model around consistent usage.
• REP Fitness Teases Digital Tech for Strength Training Data — REP Fitness, an equipment maker, is hinting at new digital strength training technology. Their Senior VP of Performance Tech, Gary Warren, said the brand wants to fill a gap for strength-specific data and insights. It's about bringing real-time metrics to your home gym without needing a dedicated coach.
• Hoka's new Clifton Pro runs stiffer, might kill off the original — US — Hoka just dropped the Clifton Pro, a stiffer, more performance-oriented version of its best-selling trainer, for just $10 more than the original. This isn't just an upgrade; it's a re-definition of what the Clifton line is, pushing it away from an easy-day shoe. Expect runners to pick favorites fast.

Signal map

Global: 52 · North America: 24 · Europe: 22 · Nordics: 3 · UK & Ireland: 3 · South Asia: 1 · Africa: 1 · Oceania: 1

What I'd watch next

Pay attention to how global bodies navigate health crises when trust is low, and how biotech responds to a fragmented regulatory landscape. Meanwhile, watch for more gym chains to partner with telehealth platforms to serve the GLP-1 generation.

Where this fits at Kokorology

These market shifts underline the need for resilient nervous system function — whether in policy-making, athletic performance, or navigating new health tech. The Nervous System Journal helps you track and build that capacity.